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Aim. Inadequately controlled diabetes accounts for chronic complications and increases mortality. Its therapeutic management
aims in normal HbA1C, prandial and postprandial glucose levels. This review discusses diabetes management focusing on the
latest insulin analogues, alternative insulin delivery systems and the artiﬁcial pancreas. Results. Intensive insulin therapy with
multiple daily injections (MDI) allows better imitation of the physiological rhythm of insulin secretion. Longer-acting, basal
insulin analogues provide concomitant improvements in safety, eﬃcacy and variability of glycaemic control, followed by low
risks of hypoglycaemia. Continuous subcutaneous insulin infusion (CSII) provides long-term glycaemic control especially in
type 1 diabetic patients, while reducing hypoglycaemic episodes and glycaemic variability. Continuous subcutaneous glucose
monitoring (CGM) systems provide information on postprandial glucose excursions and nocturnal hypo- and/or hyperglycemias.
Thisinformationenhancestreatmentoptions,providesausefultoolforself-monitoringandallowssaferachievementoftreatment
targets.Intheabsenceofacure-likepancreasorisletstransplants,artiﬁcial“closed-loop”systemsmimickingthepancreaticactivity
have been also developed. Conclusions.Individualizedtreatmentplansforinsulininitiationandadministrationmodearecriticalin
achieving target glycaemic levels. Progress in these ﬁelds is expected to facilitate and improve the quality of life of diabetic patients.
1.Introduction
Diabetes, being one of the primary causes of increased car-
diovascular morbidity and mortality in Western countries,
constitutes a large burden to health care systems in terms of
both direct and indirect costs.
Therefore, eﬃcient glucose control (attainment of nor-
mal HbA1C, prandial and postprandial glucose levels) is
essential to the prevention of life-threatening complications
of the disease.
However, most patients fail to sustain long-term, ade-
quate control through life-style modiﬁcations or even
combined oral medications [1, 2] (biguanides, sulfony-
lureas, meglitinides, glitazones, incretin mimetics, or DPP-
4 inhibitors). Indeed, multidrug therapies are currently
reconsidered,withrecentstudiesquestioningtheirlong-term
therapeutic beneﬁt over side eﬀects or disease complications
[3].
Thus, the increasing need of aggressive diabetes treat-
ment has led to the improvement of insulin therapy and its
implementation techniques. The development of continuous
subcutaneous insulin infusion (CSII) pumps and short-
acting insulin analogues exhibiting beneﬁcial pharma-
cokinetic properties represents important advances in the
treatment of diabetes and will be reviewed herein.
2. Insulin Therapy
A number of studies conﬁrm that suﬃcient glycaemic
control reduces the risk of developing diabetes-associated
complications leading to increased mortality and morbidity.
The United Kingdom Prospective Diabetes Study (UKPDS)
[4] has shown that a decrease in HbA1C by 1% is associated
with 37 and 14% reduction in the risk of microvascular and
macrovascular complications, respectively. The link between
cardiovascular risk and insuﬃcient glycaemic control has
been also conﬁrmed in numerous trials [5, 6], gradually
leading to strict guidelines, given the underlying increase
mortality and morbidity.2 Experimental Diabetes Research
Currently, ADA and IDF recommend target HbA1C
levels of <7.0 and ≤6.5%, respectively, while the jointed
ESC-EASD guidelines recommend that HbA1C target levels
should be ≤6.5% in order to reduce cardiovascular risk [7–
10].
Although strict, the oﬃcial guidelines are poorly met
within the diabetic community. In a retrospective analysis
of the United Kingdom General Practice Research database
[11] published in 2002, 76% of patients were found to have
mean HbA1C levels ≥7.0%, while on multidrug therapy
including combinations of two or more oral antidiabetic
agents (OADs). On the other hand, evidence from lifestyle
intervention studies that encouraged weight loss through
dietary changes and increased physical activity shows that
both the risk of developing diabetes and the progression of
the disease may be reduced [12, 13]. However, it is common
knowledge that no long-term patient compliance—thus
therapeutic eﬃcacy—may be expected. Inevitably, intensive
insulin therapy is to be considered for reaching HbA1C
targets, as supported by UKPDS, which showed that >60%
of type 2 diabetic patients will need insulin within 5 years of
diagnosis [4, 14].
Therapeutic algorithms suggest that during early phases
ofthedisease(whenthepancreasmaintainsitssecretoryabil-
ity) should be treated aiming to decrease insulin resistance,
then followed by basal insulin. The last therapeutic step is
the combination of basal with preprandial insulin to control
postprandial glucose ﬂuctuations [14].
Lately, there is a tendency for early initiation of insulin
administration but unfortunately, this strategy is held back
by the fear of hypoglycaemia, weight gain, and injections
[15]. Ideally, insulin therapy restores glycaemic control
without interfering with patients’ quality of life. This is
accomplished by insulin schemes restoring physiological
insulin secretion, thus controlling both baseline and post-
prandial glucose regulation. Therefore, the combinatorial
scheme of long-acting basal insulin with rapid-acting ana-
logues is becoming more popular [16]. In any case, it
should be taken into account that poorly controlled patients
need to manage fasting blood glucose (FBG) levels before
postprandial glycaemias.
Insulin preparations are characterized by the onset of
action, peak eﬀect, and duration of action. The current
classiﬁcation includes rapid, short, intermediate, and long-
acting products. The insulin’s source determines its pharma-
cokinetic characteristics.
The newer insulin analogues have several improvements
due to their modiﬁed action proﬁle [17]. Main advantages of
short-acting preparations include the faster onset of action
and shorter duration time. Long-acting analogues aﬀord
structural changes, which delay the onset of action, allow
slow and continuous absorption into the systemic circu-
lation, and prolong the duration, thus producing a time-
concentration proﬁle, which imitates the normal insulin
basal level and leads to physiological basal glycaemic control
with less nocturnal hypoglycaemias [18].
In spite of the clinical superiority, the potential mito-
genic eﬀect of some analogues remains to be clariﬁed and
constitutes a fundamental safety issue. Insulin and IGF-1
receptors display >50% of amino acid sequence homology
and even >84% in the tyrosine kinase domain, while both
ligands bind to both receptors. On the other hand, insulin
molecule modiﬁcations in the B10 and B26-B30 region alter
the aﬃnity towards the IGF-1 receptor. This has raised the
question of mitogenic potential, which may be resulting
from an enhanced aﬃnity towards the IGF-1 receptor or
because of the occupancy time of the insulin receptor by the
analogue. So far, no reliable data on this has been published
[19].
Table 1 summarizes the main characteristics of rapid and
long-acting insulin analogues described below.
3.Rapid-Acting InsulinAnalogues
3.1. Insulin Lispro. Insulin lispro [20, 21]( H u m a l o g )
(Figure 1) is the ﬁrst genetically engineered rapid-acting
insulin analogue, approved for clinical use in 1996. Its struc-
ture diﬀers from human insulin in the B-chain where proline
at position 28 and lysine at position 29 are reversed, leading
to a molecule with reduced capacity of self-association in
solution (therefore faster absorbed, with higher peak serum
levels and shorter action duration in comparison to regular
insulin). Besides glycemic management, lispro improves
the postprandial leptin and grehlin regulation of type 1
diabetic patients and may be used in cases of gestational
diabetes.
3.2. Insulin Aspart. Insulin aspart [20, 22] (NovoRapid)
(Figure 1)s t r u c t u r ed i ﬀers from human insulin at position
28 where a proline is substituted with the charged aspartic
acid, allowing it to be absorbed twice as fast as human
insulin.Itcausesbetterglycaemiccontrolwhenadministered
directly before a meal. Administration of aspart during
pregnancyoftype1diabeticwomenhasbeenassociatedwith
reduced risk of nocturnal hypoglycaemia.
3.3. Insulin Glulisine. Insulin glulisine [20, 23, 24] (Apidra)
(Figure 1)isthemostrecentrapid-actinganalogue,launched
in 2004. Its structure diﬀers in two points from human
insulin: asparagine at position 3 is substituted by lysine and
lysine at position 29 by glutamic acid. These alterations
reduce hexamers formation and enhance absorption from
subcutaneous depots. Insulins lispro and glulisine have the
same impact on the glycaemic control of type 1 diabetic
patients but when evaluating their potential on obese, type 2
diabetic subjects, the rise in insulin concentration and onset
of activity is faster for glulisine. In addition, the pharma-
cokinetic and pharmacodynamic proﬁle of glulisine does not
exhibit negative correlation with BMI and subcutaneous fat
thickness (which is the case for lispro).
4. Long-Acting Basal InsulinAnalogues
4.1. Insulin Glargine. Insulin glargine [25, 26] (Lantus)
(Figure 2) is the ﬁrst long-acting insulin analogue having
amino acid modiﬁcations in both chains. In the A-chain,
the asparagine at position 21 is substituted by glycine andExperimental Diabetes Research 3
Table 1: Main characteristics of rapid and long-acting insulin analogues.
Analogue Trade name/manufacturer Onset (min) Peak (hrs) Duration (hrs)
Long-acting analogues
Glargine Lantus/Sanoﬁ-Aventis 4–6hrs No peak >24hrs
Detemir Levemir/Novo Nordisk 4–6hrs 8–10hrs ∼17hrs
Rapid-acting analogues
Lispro Humalog/Eli Lilly 15–30min 0.5–2.5hrs 3–6.5hrs
Aspart Novorapid/Novo Nordisk 10–20min 1–3hrs 3–5hrs
Glulisine Apidra/Sanoﬁ-Aventis 10–15min 1–1.5hrs 3–5hrs
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Figure 1: The amino acid structure of rapid-acting insulin analogues. The molecular modiﬁcations on the insulin molecule are shown.
the B-chain is elongated at the C-terminus by addition
of two arginine residues. Glargine is a molecule with a
changed isoelectric point towards neutral, bearing decreased
solubility at physiological pH. This causes precipitation after
injection in subcutaneous tissue, stabilization of insulin
hexamers, delay of their dissociation, and steady absorption
into the circulation. Consequently, insulin glargine bears a
stable serum concentration without pronounced peaks and
signiﬁcantly elongated duration of action, which covers the
patient for 24 hours. Its onset of action is approximately
2 hours after injection. Compared to NPH or ultralente,
glargine aﬀords decreased hypoglycaemic events, less ﬂuctu-
ations, and lower risk of nocturnal hypoglycaemia.
4.2. Insulin Detemir. Insulin detemir [25, 27]( L e v e m i r )
(Figure 2) is characterized by acylation of myristic acid
to the lysine residue at position 29 in the B-chain and
deletion of the last threonine (position 30) in the B-chain.
Its protracted action is achieved through delayed resorp-
tion caused by the increased self-association and reversible
albumin binding at the injection site as well as because
albumin binding causes buﬀering of insulin concentration.4 Experimental Diabetes Research
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Figure 2: The amino acid structure of insulin glargine and detemir showing the key modiﬁcations that result in the prolonged duration of
action.
This results in a ﬂat, prolonged pharmacodynamic proﬁle,
which provides a metabolic eﬀect for approximately 17
hours. When compared to NPH and glargine, it oﬀers better
weight gain control and results in comparable overall risk of
hypoglycaemia.
5. ClinicalEfﬁcacy andSafety Proﬁle of
Rapidand Long-Acting InsulinAnalogues
In the Treat-to-Target study [28], insulin glargine was
compared to NPH. Both were given at bedtime starting
with 10U, with an aggressive dose titration to achieve a
fasting glucose level <100mg/dL. Both insulins resulted in
a substantial decline in fasting glucose and HbA1C, with no
diﬀerence between groups. Although the FBG target was not
achieved in many patients, ∼60% of them in both groups
achieved their target for HbA1C (<7%) within the 24-week
trial period. However, use of glargine was associated with
fewer hypoglycemias, including nocturnal ones, in relation
to NPH. Similar results have been obtained with insulin
detemir when added as basal insulin for type 2 diabetic
patients insuﬃciently controlled with OADs.
In the INSIGHT study [29] (implementing New Strate-
gies with Insulin Glargine for Hyperglycaemia Treatment),
type 2 diabetic patients (HbA1C levels 7.5–11.0%) on stable
therapy with 0–2 OADs, not including thiazolidinediones,
were randomized to either an optimised OAD regimen
(with no insulin) or initiation of bedtime glargine (with no
increase in the oral therapy). The decreases in HbA1C and
FPG were higher with glargine compared to OAD therapy
(P = .005 and P = .0001, resp.), with no diﬀerence in
hypoglycaemia incidences. The INSIGHT study proved
that early initiation of insulin glargine improves glycaemic
controlandismoreeﬀectivecomparedtooptimiseddiet/oral
therapy alone.
The Triple-Therapy Trial [30] compared patients with
type 2 diabetes insuﬃciently controlled with dual oral ther-
apy (metformin-sulfonylurea). Patients were randomised to
additionally receive either rosiglitazone or insulin glargine;
the doses of which were increased to optimise control.
Although similar improvements in HbA1C were observed
with glargine (−1.7%) and rosiglitazone (−1.5%), patients
receiving rosiglitazone experienced more hypoglycaemias,
peripheral oedema, and weight gain. At the end of the study,
more patients in the rosiglitazone group had withdrawn.
This study demonstrated that single basal insulin adminis-
tration oﬀers an eﬀective and well-tolerated alternative to
further oral drug escalation.
Although clearly demonstrated that basal analogues
provide satisfactory glycaemic control, their eﬀects on
cardiovascular outcomes have been questioned in a recent
meta-analysis comparing glargine and/or detemir with NPH
[31]. The rates of overall and nocturnal hypoglycaemias
were signiﬁcantly lower in the glargine- and detemir-
treated patients but no clinical evidence could support their
beneﬁcial eﬀect on mortality, morbidity, or quality of life.
However, longer-term studies with glargine or detemir have
repeatedly reported on the enhancement of the quality of life
and treatment satisfaction.Experimental Diabetes Research 5
The eﬀects of rapid- and long-acting analogues on
HbA1C levels have been thoroughly studied. In a review of
49 randomized clinical studies comparing analogues with
regular human insulin in type 1 diabetic patients, a mean
diﬀerence in HbA1C of −0.1% was assigned in favour of
the ﬁrst [32]. Among type 2 diabetic patients, there was
no diﬀerence between rapid-acting analogues and regular
humaninsulin.Inasimilarreviewofeightstudiescomparing
long-acting analogues with NPH in type 2 diabetic patients,
therewasnoclinicallymeaningfuldiﬀerenceinHbA1Clevels
between the two types. It should be taken into account
though that basal insulin trials are usually designed to titrate
dosing as needed to achieve preset HbA1C targets [31].
A number of studies have also assessed HbA1C levels
in patients treated with premixed human insulins versus
premixed insulin analogues, including premixed lispro and
aspart formulations [32] but the results are contradictory.
OnlyonestudyshowedsmallimprovementsinHbA1Clevels
after treatment with 50/50 premixed insulin lispro relative
to premixed human insulins, while the others favoured
premixedinsulinanalogues.Ingeneral,patientsonpremixed
insulin analogues exhibit improved postprandial glucose
controlincomparisontopremixedhumaninsulins,probably
because of the faster action of the ﬁrst [33].
The increased risk of hypoglycaemic events remains a
major disadvantage of insulin therapy, preventing physicians
from applying even more aggressive dosage schemes to lower
HbA1C levels.
In the DCCT trial [34] (Diabetes Control and Compli-
cations Trial), the incidence of severe hypoglycemias was 3-
fold higher in the intensive treatment group compared to the
conventionaltreatmentcohort(P<. 001).Moreover,therisk
of severe hypoglycemias increased as monthly HbA1C values
declined.
An interesting follow-up of the DCCT has been pub-
lished. One of the diabetes centres of the initial trial
continued to monitor HbA1C levels from 1993 to 1998 for
884 type 1 diabetic patients. During 1993 and 1996, HbA1C
continuously declined and that was evidently associated with
a signiﬁcant increase in the number of severe hypoglycemic
events (P<. 001). On 1996, when insulin lispro was
launched, 676 patients switched treatment. Surprisingly,
HbA1C levels continued to improve (P<. 001) in the
patients switched to lispro, but there was no corresponding
i n c r e a s ei nt h er a t e so fs e v e r eh y p o g l y c e m i a( P = .26)
[35]. More than that, HbA1C levels did not show further
improvement in the subjects who remained on regular
insulin.Thesedatasuggestthatintensivetherapywithinsulin
analoguesmaynotbeassociatedwiththesamehypoglycemia
risks as older formulations.
Data on rapid-acting analogues suggest a lower median
incidence of severe hypoglycemic episodes per 100 person-
years (21.8; range from 0 to 247.4) compared with regular
insulin (46.1; range from 0 to 544). Likewise, basal insulin
analogue trials exhibit signiﬁcantly lower risks of nocturnal
hypoglycemia with glargine (P = .00003) and detemir (P<
.00001) relative to NPH. The rate of severe hypoglycemia is
lower with both basal insulin analogues
[36].
Regarding the critical issue of weight gain, numerous
studies have documented that insulin-deriving improve-
ments in glycemic control are frequently accompanied by
undesirable increases in body weight [37]. In the DCCT and
the Swedish National Diabetes Register trials, modest weight
increases were negatively correlated with lipid proﬁles and
systolic blood pressure. Weight gain is highly undesirable
especially in type 2 diabetic patients given that more than
80% of them are already overweight.
Insulin-mediated weight gain has been attributed to
reduced urinary glucose excretion (calorie retention) and to
metabolic rate slow down, both resulting from the improved
glucose metabolism. The anabolic activity of insulin on both
adipose and muscle tissues may be held responsible for
prolonged periods of weight gain, even beyond the initial
p h a s eo f“ g l u c o s ec o n t r o l - r e l a t e d ”w e i g h tg a i n .T h er a t eo f
weight gain is often greatest during the early months of
therapy when glycemic control is also undergoing intensive
correction, a parameter, which may interfere with the
patient’s adjustment to insulin therapy and possibly create
an obstacle to his compliance [38].
For reasons not yet fully understood, some data indicate
that insulin detemir has a weight-sparing eﬀect [39]. Trials
in patients with type 1 and type 2 diabetes have reported
signiﬁcantly less weight gain in comparison to NPH. While
some studies have shown that patients treated with glargine
initially gain less weight in comparison to those treated
with NPH, no diﬀerence between glargine and NPH has
been noted in patients treated for 1 year. Moreover, in a
recently reported study, patients with type 2 diabetes were
switched from NPH or glargine to detemir in combination
with oral antidiabetic drugs. Fourteen weeks after the switch
to detemir, mean body weight was signiﬁcantly reduced in
patients previously using both NPH (−0.7kg; P<. 01) and
glargine (−0.5kg; P<. 05) [40].
The impact on quality of life is another factor to be
considered when administering insulin therapy. Parameters
that may deteriorate quality of life include the patient’s
concerns about needles, frequent injections, severe hypo-
glycemias, and weight gain. On the other hand, improved
glycemic control itself enhances the patient’s state of mind
and improves all aspects of everyday activities (including
sexual life), therefore motivating treatment compliance [41].
6.ContinuousSubcutaneousInsulin
Infusion (CSII)
The ﬁrst continuous subcutaneous insulin infusion (CSII)
system was developed in 1976 and had the size of a
backpack. Initial CSII indications focused on patients who
suﬀered from severe hypoglycemic episodes or hypoglycemic
unawareness and type 1 diabetic patients with dawn phe-
nomenon [42].
CSII is the implantation of an infusion system into the
surface of the body for the delivery of insulin. Currently,
it is not implanted within the body nor is a closed-loop
system. The system (Figure 3) consists of an external device
containing a computer, an insulin reservoir containing up6 Experimental Diabetes Research
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Figure 3: Main parts of an insulin pump.
to 300 units of rapid-acting insulin, and a screw-drive
pumping device. The insulin pump is attached via tubing to
asubcutaneouslyimplantedneedle(usuallyintheabdomen)
[43].
In more detail, the basic system includes an insulin
pump, a plastic needle with a stainless steel stylet for inser-
tion, which is placed in the subcutaneous tissue and plastic
tubing connecting a computer reservoir to the implanted
needle. In addition, a quick-release mechanism allows the
tubing to be disconnected from the implanted needle in the
abdomen for temporary pump interruption [44, 45]. Pump
components include
(i) a disposable plastic reservoir that is ﬁlled with
insulin,
(ii) a screw drive mechanism for “pushing” the insulin
through the plastic tubing at diﬀerent rates,
(iii) a small computer that has a memory loop designed
to dispense insulin as programmed,
(iv) a battery source for power.
CSII function is based on the physiologic endogenous
insulin secretion [46] .T h en o r m a lp a n c r e a ss e c r e t e sa
varying, basal amount of insulin throughout the day and
additional bolus amounts of insulin are secreted to cover the
increased prandial needs as a response to the carbohydrates
absorption from the gastrointestinal tract.
The ideal insulin replacement program should mimic
the above endogenous system [47]. The basal secretion is
reproduced by the constant slow infusion of rapid-acting
analogues. The rate of constant basal infusion can be altered
to meet the 24-hour requirements of each individual.
Bolus injections of rapid-acting analogues are infused
via CSII prior to meals or carbohydrate intake, controlling
postprandial glycaemias. Candidates must be well motivated
and aware of basic insulin pharmacodynamics, carbohydrate
counting, and insulin pump technology. Frequent decision-
making is required, therefore patients must be able to
assess situations and operate a computerized insulin pump.
Patients who are not achieving treatment target goals via
intensive insulin therapy are also potential candidates [48].
Table 2 summarizes current indications and contradictions
of insulin pump therapy.
The total daily dose (TDD) of insulin is calculated
based on patient weight or current insulin requirements.
If patients are switching to insulin pumps therapy from
multiple injections therapy, the TDD is initially reduced
by 20%. Alternatively, the initial dose is calculated based
on patient weight multiplied by 0.53IU/Kg (TDD = Wt
[kg] × 0.53U/kg) [49]. The total calculated basal insulin
is set on a 1-hourly basal rate, which is adjusted based on
ﬂuctuations from the target glucose level. Individual glucose
targets are set for diﬀerent clinical situations (e.g., pregnancy
or extensive physical activity) or during diﬀerent times of
the day (e.g., an increase in the basal rate is usually required
during dawn hours to oﬀset the rise in counter-regulatory
hormones GH and cortisol). The bolus insulin dosage also
takes into account the carbohydrate-to-insulin ratio (CIR)
[50].
6.1. Clinical Studies. Several studies have shown the superi-
ority of CSII over MDI in terms of HbA1C control. Among
them, the DCCT Trial [51], in which HbA1C levels in the
intensive treatment group were signiﬁcantly lower with CSII
than with MDI (−0.2t o−0.4%). To be noticed though that
the patients were allowed to choose between CSII and MDI
instead of being randomly allocated. Therefore these results
have been questioned.
Nevertheless, Pickup et al. [52] and Weissberg-Benchell
et al. [53], in their meta-analyses including more than 2100
patients, concluded on an overall advantage of CSII over
MDI, with a decrease in HbA1C 0.4–0.5% and a correspond-
ing reduction in insulin requirements.
Quality of life has been assessed in a limited number of
studies, using diﬀerent parameters and concepts. However,
Barnard et al. [54] conclude that CSII has a favourable or
neutral eﬀect on quality of life, depression, and anxiety.
Several randomized controlled trials have shown that
CSII with rapid-acting insulin analogues is more eﬃcient
for the control of postprandial glycaemia and HbA1C levels
than CSII with regular human insulin. Colquitt et al. [55]
have demonstrated that the use of insulin analogues with a
pump results in a modest (0.26%) but signiﬁcant reduction
in HbA1C compared with soluble insulin.
The eﬃcacy of CSII compared to MDI therapy has also
been evaluated in adapting insulin schemes that combine
rapid-acting with NPH insulin as basal insulin [56, 57].
The results suggest that CSII is associated with better gly-
caemiccontrol,especiallyininitiallysuboptimallycontrolled
patients.TherelativebeneﬁtofCSIIoverMDIwasgreaterfor
patients with high baseline HbA1C levels. Nevertheless, the
results obtained with CSII were superior to those achieved
with MDI, whatever the levels of baseline HbA1C.
The 5-Nations trial [58] was a randomized, controlled,
crossover trial conducted in 11 European centers, in which
272 patients were treated with CSII or MDI during a 2-
month run-in period followed by a 6-month treatment
period. The quality of glycaemic control (HbA1C levels),Experimental Diabetes Research 7
Table 2: Indications, limitations and contraindications of CSII in diabetic patients
Long-term indications
⇒ When clear proven beneﬁt over MDI
is proven and when other intensiﬁed
insulin regimens fail to achieve
adequate glycaemic control.
Short-termindications Contradictions
(1) Elevated HbA1c with MDI therapy
(2) Marked same-day or between-day glucose
levels ﬂuctuations
(3) Variability of insulin requirements
(i) Endogenous causes: dawn phenomenon
(ii) Exogenous causes: work type
particuliarities (e.g., shift workers or
business travellers)
(4) Recurrent hypoglycaemia (severe or
non-severe)
(i) Failure to maintain HbA1c targets
(<7.0%) without the occurrence of
disabling or frequent symptomatic or
asymptomatic hypoglycaemic events
(≥4/week)
(ii) Incidence of ≥1 episode(s)/year of
unexplained severe hypoglycaemia
(5) Other reasons:
(i) Allergy to insulin
(ii) Lipoatrophic diabetes
(iii) Very low insulin requirements
(1) Acute situations (e.g., in diabetology
units):
(i) For the treatment of mild ketoacidosis
or acute hyperglycaemia
(ii) For acute infections
(iii) Undergoing enteral alimentation
(2) Transient situations
(i) Severe painful neuropathy
(ii) Chronic infections, foot ulcers and all
wound-healing cicatrization situations
(iii) Pregnancy or the intention to become
pregnant
(1) Absolute Contradictions
(i) Severe psychiatric disorders
(ii) Progressive ischaemic or proliferative
retinopathy
(iii) Due to the patient’s environment or
pump:
(a) A non-educated medical
environment
(b) Living with extreme circumstances
of either heat or cold for professional
or personal reasons
(c) Underwater diving
(d) Exposure to high electromagnetic
ﬁelds (NMR)
(2) Relative Contradictions
(i) Poor compliance or patient reluctance
to live with the current management
of treatment, (e.g., frequent visits to
diabetology centre, glycaemia
monitoring, ketosis testing)
(ii) Poor local hygiene and/or
Staphylococcus presence
(iii) In some cases of end-stage renal
failure because of acidosis risk
attributed to patient incompliance
(iv) Sensory or gestural impairment
(diﬃculty with the technical aspects
of pump management)
blood glucose values, frequency of hypoglycaemic events,
and parameters of life quality were assessed. Hoogma
et al. concluded that CSII therapy oﬀers less blood glucose
variability and higher quality of life scores.
Pickup et al. [52] in his meta-analysis assessed CSII
versus MDI therapy via the evaluation of 12 random-
ized, controlled trials and showed a reduction of 0.44 in
HbA1C (conﬁdence interval: 0.20–0.69) in patients using
CSII. In addition, a reduction of up to 14% in total
daily insulin requirements was found for patients using
CSII.
The impact of basal insulin glargine on CSII therapy has
alsobeeninvestigated.Bollietal.[59]showedsimilarglucose
control with the two treatment options, while Doyle et al.
[60] in a study recruiting children showed the superiority
of CSII on HbA1C levels after 16 weeks, with signiﬁcantly
lower average insulin use. In detail, Doyle enrolled 32
conventionally treated subjects who were randomized to
either CSII or a combination of insulin glargine and bolus
doses of aspart. The CSII group was found to have lower
HbA1C levels in comparison to both glargine group and the
baseline HbA1C levels. FPG concentrations did not diﬀer
between the 2 groups, indicating similar adequacy of basal
insulin replacement. However, SMBG performed at lunch,
dinner, and bedtime demonstrated signiﬁcantly lower blood
glucose levels in the CSII group, suggesting that lack of
compliance with bolus dosing contributes to higher blood
glucose and HbA1C levels in the MDI group. In addition,
preprandial and bedtime blood glucose values were lower;
whereas prebreakfast values were similar, indicating better
coverage with CSII. Hirsch et al. [61] in a randomized,
crossover study in adults comparing CSII and MDI with
insulinreportedonlowerfructosaminelevelsandfewerdaily
glycaemic excursions with CSII, as assessed by continuous
glucose monitoring.
Most studies point out the fact that CSII superiority
dependsonpatientscreeningandpre-CSIIglycaemicproﬁle.
Inaretrospectiveanalysisofdatafrom17diabetesoutpatient
clinics in Sweden, Fahl´ en et al. [62] showed that switching
from MDI without long-acting analogues to CSII improved
metabolic control, with a more pronounced eﬀect associated
with CSII, particularly in patients with higher HbA1C levels
and BMI at baseline.
In all, clinical studies indicate that adult patients, with
type 1 diabetes mellitus, are favoured by CSII treatment
in comparison to MDI therapy and are led to a better
glycaemic control with less hypoglycaemic episodes and
insulin requirements [63].8 Experimental Diabetes Research
6.2. CSII in Paediatric Patients. T h e r ei sp l e n t yo fe v i d e n c e
that both children and adolescents are favoured by CSII
equally or more than MDI [64]( Table 3). Cohort studies
provide evidence of a signiﬁcant beneﬁt when paediatric
patients on MDI are converted to CSII.
For example, Weinzimer et al. [65] found that HbA1C
levels continued to fall 4 years after conversion to CSII in
young children (mean age 4.5 years; n = 65). Sulli and
Shashaj [66] have discussed the long-term beneﬁts of CSII
observed in older children, with a mean age of 12 years
(n = 42), followed-up for 4 years after therapy initiation.
Recently, Jakisch et al. [67]r e p o r t e do nap r o s p e c t i v es t u d y
of paediatric patients initiated on CSII or MDI in Germany
(n = 434 matched pairs). Superior HbA1C control was
achieved by CSII during the ﬁrst year (7.5% versus 7.7%
with MDI; P<. 006) but was not maintained until the
third (8.1% versus 8.0%, resp.; P<. 99). However, CSII
was associated with statistically signiﬁcant reductions in
hypoglycaemic and DKA episodes and insulin requirements
throughout the follow-up period. Weinzimer et al. [68]
randomized almost 300 children and adolescents to 16 weeks
of CSII therapy with insulins lispro or aspart. Although a
numerically greater reduction in HbA1C with aspart did
not reach statistical signiﬁcance, more patients treated with
aspart (59.7%) achieved target HbA1C levels compared with
patients treated with lispro (43.8%; P<. 04).
Hypoglycaemic episodes constitute an obstacle for many
insulin-treated children especially when low glycaemic tar-
gets are set. In principle, CSII should reduce the risk
of hypoglycaemia. Indeed, Pickup and Sutton [69]i na
recent meta-analysis of 21 studies showed that CSII was
associated with a 75% lower rate of severe hypoglycaemia
compared to MDI. The reduction in hypoglycaemia was
the greatest in patients with a high hypoglycaemia rate
while on MDI. On the other hand, convenience should
be secured to children, for whom MDI administration
becomes frustrating when trying to achieve hard glycaemic
targets. CSII is more convenient with regard to injection
frequency, as the subcutaneous cannula needs to be resited
once every 2-3 days. McVean et al. [70] partially attribute the
eﬀectiveness of CSII in children to the number of cannula
sites used, perhaps due to improved insulin absorption.
CSII has been shown to improve the well-being of both
children with type 1 diabetes and their parents. Treatment
satisfaction is higher among children randomized to CSII
than MDI. Recently, Hanas and Ludvigsson [71]d e t e c t e d
a small increase in DKA in paediatric patients treated with
CSII, as compared with MDI, especially early after CSII
initiation. Contradicting that, Jakisch et al. [67]f o u n d
that a lower baseline incidence of DKA in the CSII group
was maintained throughout the 3 years of follow-up of
h i st r i a l .D K Ai np u m pu s e r si sm o s tl i k e l yt oo c c u r
when patients do not realize the malfunctioning of the
pump. Thus, proper training and monitoring can minimize
the problem. Type 1 diabetic children and adolescents
beneﬁt an improved quality of life [72–75]a n ds u ﬃcient
glycaemic control when switching to CSII as long as they
get accustomed to the mechanical aspects of their treat-
ment.
6.3. CSII in Pregnancy. Glycaemic control is crucial during
pregnancy for both mother and foetus, because of the close
relationship between blood glucose levels and pregnancy
outcome [76]. However, achieving stable glucose levels dur-
ing pregnancy is challenging because of the increased risk of
hypoglycaemia due to the passive diﬀusion of glucose across
theplacentaandchangesofcounter-regulatoryhormones.In
addition, glycaemic control maintenance is diﬃcult because
of the continuous insulin requirement alterations, which are
decreased in the ﬁrst trimester and increased in the second
half of pregnancy [77].
The use of CSII during pregnancy dates back to the early
1980s. Initially, CSII was used during the third trimester to
prevent macrosomia, but later its use was extended. CSII
can be safely started during pregnancy, but it is preferable to
start before conception, in order to minimize malformations
risk and allow proﬁciency with the pump. Potential patients
should be compliant with capillary glucose testing (8 to 10
times a day) and willing to monitor ketone bodies [78].
According to ADA guidelines, the goal for FPG before
meal should be ≤105mg/dL, while the 2 hours postprandial
plasma glucose should not exceed 130mg/dl. Currently,
insulinslisproandaspartareindicatedforadministrationvia
CSII in gestational diabetes [79].
The majority of the studies conducted in pregnant
women are observational involving both types 1 and 2
diabetic patient [80]. The number of randomized, controlled
trials comparing CSII and MDI is scarce and include a
relatively small number of participants. Mukhopadhyay et
al. [81] attempted to review the available data and meta-
analyzed 6 studies with a total of 213 pregnant diabetic
women randomized on CSII or MDI therapy. Data evalua-
tion considered the weighted mean diﬀerence and odds ratio
for insulin dose, birth weight, gestational age, delivery mode,
hypoglycemic episodes, worsening retinopathy, neonatal
hypoglycemia, and rates of intrauterine fetal death. Preg-
nancy outcomes and glycemic control were not signiﬁcantly
diﬀerent among treatment groups. Yet, a higher number
of DKA episodes and diabetic retinopathy were found in
the CSII group (not statistically signiﬁcant). The authors
could not conclude on the superiority of one treatment
and suggested that large multicenter, randomized, controlled
trials are required for this patients group.
Although a clear-cut advantage of CSII over MDI during
pregnancydoesnotemergefromtheliterature,CSIIprovides
greater ﬂexibility in lifestyle, allows an easier control of
morning nausea, decreases the number of hypoglycaemic
episodes, decreases blood glucose variability, alleviates the
dawn phenomenon, copes more easily with delayed gastric
emptying, and eases blood glucose control around delivery
[82].
7.ContinuousSubcutaneousGlucose
Monitoring(CGM)
The DCCT trial [34] established the correlation of suﬃ-
cient glucose control with reduced microvascular compli-
cations risk. Frequent glucose monitoring was found toExperimental Diabetes Research 9
Table 3: CSII therapy in pediatric patients.
Currentindications
Recurrent severe hypoglycemia
Wide ﬂuctuations in blood glucose levels regardless of HbA1c
Suboptimal diabetes control
Microvascular complications and/or risk factors for macrovascular complications
Good metabolic control but insulin regimen that compromises lifestyle (e.g., competitive athletes and needle phobia)
Adolescents with eating disorders
Children and adolescents with a pronounced dawn phenomenon
Ketosis-prone individuals
Advantages of CSIIcompared with MDI in children
Easier and convenient adjustment of bolus insulin dose and nocturnal basal insulin dose
Greater accuracy of insulin dosage
Easier management of infectious illnesses and hyperglycemic episodes
Quality of life improvement
Less injections ⇒ Less anxiety ⇒ better compliance
Flexibility of everyday activities
be a determining factor for the achievement of glucose
control.
Upuntilafewyearsago,self-monitoringofbloodglucose
(SMBG) was considered eﬀective for both types of diabetes
since it contributed to the improvement of HbA1C and the
delay of long-term diabetes complications [83]. However,
this technique has suﬀered some drawbacks. Noninsulin
treated diabetic patients show minimum compliance on
the grounds of inconvenience and unnecessary pain. On
the other hand, measurements scheduling is often poor
resulting in useless, incorrectly interpreted information
not applicable to an individualized therapy. However, and
despite the above diﬃculties, SMBG is recommended for
the management of diabetes in all the major guidelines
[84].
On the other hand, continuous glucose monitoring
(CGM) provides detailed information regarding blood glu-
cose ﬂuctuations throughout the day, enabling treatment
decisions for the diabetic patient. Compared with SMBG,
continuous monitoring provides much greater insight into
glucose levels throughout the day, enabling the detection
of postprandial glucose excursions and nocturnal hypo-
glycemias or hyperglycemias even in patients whose HbA1C
levels suggest a satisfactory blood glucose control [85, 86].
Visualization of the glucose curve over time in relation
to meals consumed and exercise assists the patient to
comprehend the importance of dosage adjustments. The
graphs shown by CGM further enable the patient to self-
manage his glucose levels according to his activities and
lifestyle. Even more important, the visible data of “on-line”
or unblinded systems of CGM help the patient realize the
real-time eﬀects of acute treatment decisions as well as their
delayed eﬀects [87].
There are several devices for CGM but only two are
usually used. One is the Holter-type of glucose monitoring,
where results are shown and analyzed retrospectively; the
second uses real-time presentation of glycaemic values. The
CGMS of Medtronic (Minimed, Northridge, CA, USA) was
the ﬁrst device approved and remains popular both in USA
and Europe. It provides a retrospective graphical view of
the glycaemic proﬁle measured during the last three days
[88].
During the years, both invasive and noninvasive CGM
techniques have been developed but up to now, only the ﬁrst
have been approved for clinical use. The invasive techniques
include the insertion of a subcutaneous glucose sensor that
measures interstitial ﬂuid glucose as it osmotically diﬀuses
from the peri-capillary area towards the cells, using either
enzymatic (glucose oxidase) or microdialysis technology.
Interstitial glucose may lag behind blood glucose by as
m u c ha s2 0m i n u t e sw h e nb l o o dg l u c o s el e v e l sa r ec h a n g i n g
rapidly. These devices require calibration using capillary
blood determinations. Each sensor continuously measures
glucose levels for up to 3–7 days, giving a read-out every
1–10 minutes. The presently available CGM devices provide
either historic readouts or real-time reporting. They are
also equipped with alarms warning of impending hypo or
hyperglycemia [89].
CGM requires thorough education of both the patient
and the physician in order to use the readings properly
for the adjustment of treatment. Furthermore, the optimal
use of CGM requires the ability to perform blood deter-
minations necessary for calibration. It should be noticed,
that to date, CGM systems have not been approved for
replacement of traditional SMBG devices, which should be
used when continuous monitoring results do not reﬂect the
way the patient feels, prior to medication administration or
responding to threshold alarms and certainly when the CGM
system is being calibrated so as to ensure accuratecalculation
of glucose readings [90].
So far, CGM is indicated [91]
(i) to observe and determine glucose ﬂuctuations: its
magnitude,duration,frequencyandpotentialcauses,
(ii) to determine the amount of time a patient spends in
out-of normal glucose ranges,10 Experimental Diabetes Research
(iii) to diagnose and prevent hypoglycemia,
(iv) To determine the impact of lifestyle modiﬁcation and
diet composition on glucose control,
when screening patients for CGM usage, the physician
should also take into account some of its current drawbacks
[92, 93] and most importantly the:
(i) inaccuracy of single point measurements compared
to SMBG, particularly in hypoglycemic levels,
(ii) delay of glucose measurements,
(iii) disparity of interstitial glucose measurements,
(iv) need for frequent recalibration.
Furthermore, the technique is invasive and patients tend
to reject it. The fact that the technology is best in real-
time function constitutes another problem because of the
intensive education required before being able to make real-
time therapeutic decisions. The cost is also a matter to
consider given that reimbursement is not available in many
countries.
In conclusion, CGM technologies continuously improve
and tend to be incorporated into everyday practice of
diabetic management. Therefore, more interventional trials
evaluating the eﬀects of glucose ﬂuctuations on diabetic
complications should be conducted to enhance their eﬃ-
ciency and safety.
8.Artiﬁcial“Closed-Loop”
Systems—ArtiﬁcialPancreas
Continuous subcutaneous glucose sensing (CGS) is the
most recent advance in the control of serum glucose.
Real-time continuous glucose sensors have the potential to
revolutionize the treatment of diabetes mellitus.
Aclosedloopsystemmonitorsglucoselevelsandsupplies
insulin accordingly [94]. The ideal closed-loop system, or
“artiﬁcial pancreas,” should contain three basic elements
[95]:
(i) a safe-delivery device that stores and releases insulin
reliably and accurately (insulin pump),
(ii) an accurate, biocompatible glucose-sensing unit
potent of frequent or continuous sampling (control
algorithm),
(iii) a control system modulating insulin delivery, glucose
and maybe glucagon or amylin according to blood
glucose levels (continuous monitor).
Additionally, the microcomputer system in an artiﬁcial
pancreas will sample, ﬁlter, and interpret the glucose sensor
data, to compare the reading with allowable norms and to
accurately control insulin in order to achieve normalized
blood glucose levels. This process should operate contin-
uously without mistakes so as to avoid errors leading to
severe hypo- or hyperglycemias. This autonomous function
is supposed to resemble glucose responsive insulin secretion
fromthepancreasandshouldbeafullyclosedloopapproach
[96].
Unfortunately, the accuracy of the current continuous
glucose sensors and algorithms is not yet suﬃcient to permit
thelooptobeclosed.Theopenlooprequiresnoautonomous
control system, as it is the patient who manages insulin
delivery on the basis of blood glucose data provided by the
sensor.The closedloop, ontheotherhand,requiresacontrol
algorithm to adjust the administered insulin dose according
tobloodglucoselevels[97].Thefeasibilityofthistherapyhas
been demonstrated in small studies but its performance has
not been tested for home use.
Currently, two modalities are being developed.
The ﬁrst is an extracorporeal subcutaneous-subcu-
taneous approach [98] that utilizes subcutaneous glu-
cose monitoring combined with subcutaneously delivered
insulin. The minimally invasive nature of this system oﬀers
a strong advantage. Its most important drawback lies in the
lag time between glucose measurement and insulin delivery,
which may be up to 40 minutes followed by the rapid-acting
analogue administration, which requires up to 15 minutes
for an eﬀect to occur.
The second is an implantable intravenous–intraperito-
neal system [99] in which glucose monitoring occurs intra-
venously and insulin delivery is performed intraperitoneally.
This approach has a greater chance to achieve a fully closed
loop system. The delays in the system are shorter than
with the subcutaneous-subcutaneous method but it still
has longer physiologic delays. With the implantable insulin
delivery pump, insulin is introduced into the peritoneum,
which is closer to physiologic delivery and absorption.
There are several obstacles in the development of an
artiﬁcial pancreas [100, 101], one of which lies in the
physiological diﬀerence between variations in interstitial
glucoseandplasmaglucoselevels.Thesystemhastotakeinto
account the time for the sensor to measure the glucose, the
time taken by the subcutaneous absorption of insulin and
the irreducible time required for insulin action. The total
amount creates a certain inertia depending on the speed of
changes in plasma glucose concentrations. Another diﬃculty
arises from controlling the rapid, postprandial blood glucose
ﬂuctuations. This is why a “mixed” open/closed concept
[102] is currently being developed applying hybrid use of
the algorithm: autonomous operation (closed loop) during
the fasting and interprandial periods and manual, nonau-
tonomous operation of the prandial bolus programmed by
the patient according to meal time or composition (open
loop).
9. Conclusions
The goal of diabetes treatment is to achieve tight glucose
control,avoidchroniccomplications andlimit hypoglycemic
episodes frequency in everyday life.
Remarkable improvement has been made on this ﬁeld
with the introduction of insulin analogues. The rapid-
acting analogues eﬃciently control postprandial glucose
levels while the long-acting analogues imitate the normal
insulin basal level and lead to physiological basal glycaemic
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On the other hand, CSII technology has revolutionalized
the way insulin therapy is implemented, providing conve-
nient and ﬂexible insulin delivery during routine treatment
in children and adolescents improving their quality of life
and glycaemic control.
However, despite the considerable eﬀorts to improve
insulin pharmacokinetics and develop user-friendly moni-
tors and miniaturized insulin pumps, the goal has not yet
beenachieved,thusresearchonautomatedartiﬁcialpancreas
is in progress. Considerable work remains to be completed
before algorithms for the automated regulation of glucose
levels become available.
Other strategies for diabetes management are also on
way. The transplantation of islets of Langerhans was made
possible by developing new isolation and immunosuppres-
sant methods. Nevertheless, their rate of success is still low
and the number of donors remains insuﬃcient. Insulin
secretingcellsarecreatedinvitrobuttheyarefarfromhaving
the same response to glucose as the genuine β-cells.
Finally, biosystems aiming to mimick natural feedback
by combining sensor function (to perceive glucose modiﬁca-
tion) and eﬀector function (insulin delivery) are also under
development in order to improve the everyday life of the
diabetic patient.
The ultimate challenge on this ﬁeld remains a device,
which would aﬀord
(i) sensor speciﬁcity in a way that the sensor will only
respond to glucose variations,
(ii) pharmacokinetics similar to normal pancreatic activ-
ity,
(iii) administration comfort by simple long lasting injec-
tions (ideally one subcutaneous injection per week or
month).
References
[1] S. Brunton, “Beyond glycemic control: treating the entire
type 2 diabetes disorder,” Postgraduate Medicine, vol. 121, no.
5, pp. 68–81, 2009.
[2] M. E. Cobble and A. L. Peters, “Clinical practice in type
2 diabetes: after metformin and lifestyle, then what?” The
JournalofFamilyPractice,vol.58,supplement11,pp.S7–S14,
2009.
[3] J. Philippe and D. Raccah, “Treating type 2 diabetes: how
safe are current therapeutic agents?” International Journal of
Clinical Practice, vol. 63, no. 2, pp. 321–332, 2009.
[4] United Kingdom Prospective Diabetes Study Group, “Inten-
sive blood-glucose control with sulphonylureas or insulin
compared with conventional treatment and risk of compli-
cations in patients with type 2 diabetes (UKPDS 33),” Lancet,
vol. 352, pp. 837–853, 1998.
[5] E. Selvin, K. Wattanakit, M. W. Steﬀes, J. Coresh, and A. R.
Sharrett, “HbA1c and peripheral arterial disease in diabetes:
the atherosclerosis risk in communities study,” DiabetesCare,
vol. 29, no. 4, pp. 877–882, 2006.
[6] M. Meier and M. Hummel, “Cardiovascular disease and
intensive glucose control in type 2 diabetes mellitus: moving
practice toward evidence-based strategies,” Vascular Health
and Risk Management, vol. 5, pp. 859–871, 2009.
[7] D. M. Nathan, J. B. Buse, M. B. Davidson, et al., “American
diabetes association; european association for study of
diabetes. Medical management of hyperglycemia in type 2
diabetes: a consensus algorithm for the initiation and adjust-
ment of therapy: a consensus statement of the American
Diabetes Association and the European Association for the
study of diabetes,” Diabetes Care, vol. 32, no. 1, pp. 193–203,
2009.
[8] D. M. Nathan, J. B. Buse, M. B. Davidson, et al., “American
diabetes association and the European association for the
study of diabetes. Medical management of hyperglycaemia
in type 2 diabetes mellitus: a consensus algorithm for the
initiation and adjustment of therapy : aconsensus statement
from the ,” Diabetologia, vol. 52, no. 1, pp. 17–30, 2009.
[9] British Cardiac Society, British Hypertension Society, Dia-
betes UK, et al., “JBS 2: prevention of cardiovascular disease
in clinical practice,” Heart, vol. 91, supplement 5, pp. v1–v52,
2005.
[10] L. Rydn, E. Standl, M. Bartnik, et al., “Guidelines on
diabetes, pre-diabetes, and cardiovascular diseases: executive
summary. The task force on diabetes and cardiovascular
diseases of the European Society of Cardiology (ESC) and of
the European Association for the Study of Diabetes (EASD),”
European Heart Journal, vol. 28, no. 1, pp. 88–136, 2007.
[11] K. M. Fox, R. A. Gerber, B. Bolinder, J. Chen, and S. Kumar,
“Prevalence of inadequate glycemic control among patients
with type 2 diabetes in the United Kingdom general practice
research database: a series of retrospective analyses of data
from 1998 through 2002,” Clinical Therapeutics, vol. 28, no.
3, pp. 388–395, 2006.
[12] W. C. Knowler, S. E. Fowler, R. F. Hamman, et al., “10-
year follow-up of diabetes incidence and weight loss in the
diabetes prevention program outcomes study,” The Lancet,
vol. 374, no. 9702, pp. 1677–1686, 2009.
[13] T. D. Giles, “Prevention of type 2 diabetes mellitus to reduce
cardiovascular morbidity and mortality: a review of the
evidence,” Journal of Clinical Hypertension,v o l .1 1 ,n o .9 ,p p .
512–519, 2009.
[14] M. E. Cobble, “Initiating and intensifying insulin therapy for
type 2 diabetes: why, when, and how,” American Journal of
Therapeutics, vol. 16, no. 1, pp. 56–64, 2009.
[15] W.C.Hsu,“Consequencesofdelayingprogressiontooptimal
therapy in patients with type 2 diabetes not achieving
glycemic goals,” Southern Medical Journal, vol. 102, no. 1, pp.
67–76, 2009.
[16] D. Kerr, “Individualism and insulin pump therapy,” Dia-
betologia, vol. 52, no. 2, pp. 362–363, 2009.
[17] D. S.H. Bell, “Insulin therapy in diabetes mellitus: how can
the currently available injectable insulins be most prudently
and eﬃcaciously utilised?” Drugs, vol. 67, no. 13, pp. 1813–
1827, 2007.
[18] B. Sheldon, D. Russell-Jones, and J. Wright, “Insulin ana-
logues: an example of applied medical science,” Diabetes,
Obesity and Metabolism, vol. 11, no. 1, pp. 5–19, 2009.
[19] S. K. Garg, I. B. Hirsch, and J. S. Skyler, “Insulin glargine and
cancer-an unsubstantiated allegation,” Diabetes Technology
and Therapeutics, vol. 11, no. 8, pp. 473–476, 2009.
[20] K. Eckardt and J. Eckel, “Insulin analogues: action proﬁles
beyond glycaemic control,” Archives Physiol Biochem, vol.
114, no. 1, pp. 45–153, 2008.
[21] D. Giugliano, A. Ceriello, E. Razzoli, and K. Esposito,
“Deﬁning the role of insulin lispro in the management of
postprandial hyperglycaemia in patients with type 2 diabetes12 Experimental Diabetes Research
mellitus,” Clinical Drug Investigation, vol. 28, no. 4, pp. 199–
210, 2008.
[22] T. M. Chapman, S. Noble, and K. L. Goa, “Spotlight on
insulin aspart in type 1 and 2 diabetes mellitus,” Treatments
in Endocrinology, vol. 2, no. 1, pp. 71–76, 2003.
[23] R. H. A. Becker, “Insulin glulisine complementing basal
insulins: a review of structure and activity,” Diabetes Tech-
nology and Therapeutics, vol. 9, no. 1, pp. 109–121, 2007.
[24] K. P. Garnock-Jones and G. L. Plosker, “Insulin glulisine: a
review of its use in the management of diabetes mellitus,”
Drugs, vol. 69, no. 8, pp. 1035–1057, 2009.
[25] E.G.H agenmeyer ,P .K.Sch¨ adlich,A.D .K¨ oster,F.-W.Dippel,
and B. H¨ aussler, “Quality of life and treatment satisfaction
in patients being treated with long-acting insulin analogues,”
Deutsche Medizinische Wochenschrift, vol. 134, no. 12, pp.
565–570, 2009.
[26] M. A. Elrishi, J. Jarvis, K. Khunti, and M. J. Davies,
“Insulin glargine and its role in glycaemic management of
Type 2 diabetes,” Expert Opinion on Drug Metabolism and
Toxicology, vol. 4, no. 8, pp. 1099–1110, 2008.
[27] J. Morales, “Deﬁning the role of insulin detemir in basal
insulin therapy,” Drugs, vol. 67, no. 17, pp. 2557–2584, 2007.
[28] M. C. Riddle, J. Rosenstock, and J. Gerich, “The treat-to-
target trial: randomized addition of glargine or human NPH
insulin to oral therapy of type 2 diabetic patients,” Diabetes
Care, vol. 26, no. 11, pp. 3080–3086, 2003.
[29] H. C. Gerstein, J.-F. Yale, S. B. Harris, M. Issa, J. A.
Stewart, and E. Dempsey, “A randomized trial of adding
insulin glargine vs. avoidance of insulin in people with
Type 2 diabetes on either no oral glucose-lowering agents
or submaximal doses of metformin and/or sulphonylureas.
The Canadian INSIGHT (implementing new strategies with
Insulin glargine for hyperglycaemia treatment) Study,” Dia-
betic Medicine, vol. 23, no. 7, pp. 736–742, 2006.
[30] J.Rosenstock,D.Sugimoto,P.Strange,J.A.Stewart,E.Soltes-
Rak, and G. Dailey, “Triple therapy in type 2 diabetes: insulin
glargine or rosiglitazone added to combination therapy
of sulfonylurea plus metformin in insulin-naive patients,”
Diabetes Care, vol. 29, no. 3, pp. 554–559, 2006.
[31] K. Horvath, K. Jeitler, A. Berghold, and S. H. Ebrahim,
“Long-acting insulin analogues versus NPH insulin (human
isophane insulin) for type 2 diabetes mellitus,” Cochrane
Database of Systematic Reviews, vol. 18, no. 2, Article ID
CD005613, 2007.
[32] R.Qayyum, S.Bolen,N.Maruthur,et al.,“Systematic review:
comparative eﬀectiveness and safety of premixed insulin
analoguesintype2diabetes,”AnnalsofInternalMedicine,vol.
149, no. 8, pp. 549–559, 2008.
[33] S. C. L. Gough, “A review of human and analogue insulin
trials,” Diabetes Research and Clinical Practice, vol. 77, no. 1,
pp. 1–15, 2007.
[34] H. Shamoon, H. Duﬀy, N. Fleischer, et al., “The eﬀect of
intensive treatment of diabetes on the development and pro-
gression of long-term complications in insulin-dependent
diabetes mellitus,” New England Journal of Medicine, vol. 329,
no. 14, pp. 977–986, 1993.
[35] H.P.Chase,T.Lockspeiser,B.Peery,etal.,“Theimpactofthe
diabetes controlandcomplications trialandhumaloginsulin
on glycohemoglobin levels and severe hypoglycemia in type
1 diabetes,” Diabetes Care, vol. 24, no. 3, pp. 430–434, 2001.
[36] M. Monami, N. Marchionni, and E. Mannucci, “Long-acting
insulin analogues vs. NPH human insulin in type 1 diabetes.
A meta-analysis,” Diabetes, Obesity and Metabolism, vol. 11,
no. 4, pp. 372–378, 2009.
[37] L. Meneghini, “Demonstrating strategies for initiation of
insulin therapy: matching the right insulin to the right
patient,” International Journal of Clinical Practice, vol. 62, no.
8, pp. 1255–1264, 2008.
[38] F.X.Pi-Sunyer,“Theeﬀectsofpharmacologicagentsfortype
2 diabetes mellitus on body weight,” Postgraduate Medicine,
vol. 120, no. 2, pp. 5–17, 2008.
[39] M. A. Bush, “Intensive diabetes therapy and body weight:
focus on insulin detemir,” Endocrinology and Metabolism
Clinics of North America, vol. 36, supplement 1, pp. 33–44,
2007.
[40] A. Dornhorst, H.-J. L¨ uddeke, C. Koenen, et al., “Transferring
to insulin detemir from NPH insulin or insulin glargine
in type 2 diabetes patients on basal-only therapy with oral
antidiabetic drugs improves glycaemic control and reduces
weight gain and risk of hypoglycaemia: 14-week follow-up
data from PREDICTIVE,” Diabetes, Obesity and Metabolism,
vol. 10, no. 1, pp. 75–81, 2008.
[41] I. Hartman, “Insulin analogs: impact on treatment success,
satisfaction, quality of life, and adherence,” Clinical Medicine
and Research, vol. 6, no. 2, pp. 54–67, 2008.
[42] G. Scheiner, R. J. Sobel, D. E. Smith, et al., “Insulin
pump therapy guidelines for successful outcomes,” Diabetes
Educator, vol. 35, supplement 2, pp. 29S–41S, 2009.
[43] H. Hanaire, V. Lassmann-Vague, N. Jeandidier, et al., “Treat-
ment of diabetes mellitus using an external insulin pump:
the state of the art,” Diabetes and Metabolism,v o l .3 4 ,n o .4 ,
supplement 1, pp. 401–423, 2008.
[44] J. Sherr and W. V. Tamborlane, “Past, present, and future of
insulinpumptherapy:bettershotatdiabetescontrol,”Mount
Sinai Journal of Medicine, vol. 75, no. 4, pp. 352–361, 2008.
[45] L. G. Potti and S. T. Haines, “Continuous subcutaneous
insulininfusiontherapy:aprimeroninsulinpumps,”Journal
of the American Pharmacists Association, vol. 49, no. 1, pp. 1–
13, 2009.
[46] R. D. White, “Insulin pump therapy (continuous subcuta-
neous insulin infusion),” Primary Care, vol. 34, no. 4, pp.
845–871, 2007.
[47] R. D. R. Liberatore and D. Damiani, “Insulin pump therapy
in type 1 diabetes mellitus,” Jornal de Pediatria,v o l .8 2 ,n o .4 ,
pp. 249–254, 2006.
[48] T. Ulahannan, N. N. Myint, and K. F. Lonnen, “Making the
case for insulin pump therapy,” Practical Diabetes Interna-
tional, vol. 24, no. 5, pp. 252–256, 2007.
[49] N. Jeandidier, J.-P. Rivelineb, N. Tubiana-Ruﬁ, et al., “Treat-
ment of diabetes mellitus using an external insulin pump
in clinical practice,” Diabetes and Metabolism,v o l .3 4 ,n o .4 ,
supplement 1, pp. 425–438, 2008.
[50] N. Siddiqui, S. Rahman, and A. Nessa, “Development of
insulin delivery systems,” Mymensingh Medical Journal, vol.
17, no. 1, pp. 102–110, 2008.
[51] H. Shamoon, H. Duﬀy, N. Fleischer, et al., “Implementation
of treatment protocols in the diabetes control and complica-
tions trial,” Diabetes Care, vol. 18, no. 3, pp. 361–376, 1995.
[52] J. Pickup, M. Mattock, and S. Kerry, “Glycemic control
with continuous subcutaneous insulin infusion compared
with intensive insulin injections in patients with type 1
diabetes: meta-analysis of randomized controlled trials,”
British Medical Journal, vol. 324, pp. 705–708, 2002.
[53] J. Weissberg-Benchell, J. Antisdel-Lomaglio, and R. Seshadri,
“Insulin pump therapy: a meta-analysis,” Diabetes Care, vol.
26, no. 4, pp. 1079–1087, 2003.Experimental Diabetes Research 13
[54] K. D. Barnard, C. E. Lloyd, and T. C. Skinner, “Systematic
literature review: quality of life associated with insulin pump
use in type 1 diabetes,” Diabetic Medicine, vol. 24, no. 6, pp.
607–617, 2007.
[55] J. Colquitt, P. Royle, and N. Waugh, “Are analogue insulins
better than soluble in continuous subcutaneous insulin
infusion? Results of a meta-analysis,” Diabetic Medicine, vol.
20, no. 10, pp. 863–866, 2003.
[56] R.Retnakaran,J.Hochman,J.H.DeVries,etal.,“Continuous
subcutaneous insulin infusion versus multiple daily injec-
t i o n s .T h ei m p a c to fb a s e l i n eA 1c,” Diabetes Care, vol. 27, no.
11, pp. 2590–2596, 2004.
[57] R. Retnakaran, J. H. DeVries, H. Hanaire-Broutin, R. J.
Heine, V. Melki, and B. Zinman, “Continuous subcutaneous
insulin infusion versus multiple daily injections. Modeling
predicted beneﬁts in relationship to baseline A1c,” Diabetes
Care, vol. 28, no. 7, pp. 1835–1836, 2005.
[58] R. P. L. M. Hoogma, P. J. Hammond, R. Gomis, et al.,
“Comparison of the eﬀects of continuous subcutaneous
insulininfusion(CSII)andNPH-basedmultipledailyinsulin
injections (MDI) on glycaemic control and quality of life.
Results of the 5-nations trial,” Diabetic Medicine, vol. 23, no.
2, pp. 141–147, 2006.
[59] B.Bolli,F.Capani,P.Home,etal.,“Comparisonofamultiple
daily injection daily with once-daily insulin glargine basal
insulin and mealtime lispro, to continuous subcutaneous
insulin infusion: a randomised, open, parallel study,” Dia-
betes, vol. 53, supplement 2, pp. A107–A108, 2004.
[60] E. A. Doyle, S. A. Weinzimer, A. T. Steﬀe n ,J .A .H .A h e r n ,M .
Vincent, and W. V. Tamborlane, “A randomized, prospective
trial comparing the eﬃcacy of continuous subcutaneous
insulin infusion with multiple daily injections using insulin
glargine,” Diabetes Care, vol. 27, no. 7, pp. 1554–1558, 2004.
[61] B. Hirsch, B.Bode, S. Garg, etal., “Continuous subcutaneous
insulin infusion (CSII) of insulin aspart versus multiple daily
injection of insulin aspart/insulin glargine in type 1 diabetic
patients previously treated with CSII,” Diabetes Care, vol. 28,
pp. 533–538, 2005.
[62] M. Fahl´ en, B. Eliasson, and A. Oden, “Optimization of basal
insulin delivery in type 1 diabetes: a retrospective study on
the use of continuous subcutaneous insulin infusion and
insulin glargine,” Diabetic Medicine, vol. 22, no. 4, pp. 382–
386, 2005.
[63] I. Aberle, D. Zimprich, B. Bach-Kliegel, et al., “Continuous
subcutaneous insulin infusion leads to immediate, stable and
long-term changes in metabolic control,” Diabetes, Obesity
and Metabolism, vol. 10, no. 4, pp. 329–335, 2008.
[64] W. V. Tamborlane, K. Swan, K. A. Sikes, A. T. Steﬀen, and S.
A. Weinzimer, “The renaissance of insulin pump treatment
in childhood type 1 diabetes,” Reviews in Endocrine and
Metabolic Disorders, vol. 7, no. 3, pp. 205–213, 2006.
[65] S. A. Weinzimer, J. H. Ahern, E. A. Doyle, et al., “Persistence
of beneﬁts of continuous subcutaneous insulin infusion in
veryyoungchildrenwithtype1diabetes:afollow-upreport,”
Pediatrics, vol. 114, no. 6, pp. 1601–1605, 2004.
[66] N. Sulli and B. Shashaj, “Long-term beneﬁts of continuous
subcutaneous insulin infusion in children with type 1
diabetes: a 4-year follow-up,” Diabetic Medicine, vol. 23, no.
8, pp. 900–906, 2006.
[67] B. I. Jakisch, V. M. Wagner, B. Heidtmann, et al., “Compari-
son of continuous subcutaneous insulin infusion (CSII) and
multiple daily injections (MDI) in paediatric type 1 diabetes:
a multicentre matched-pair cohort analysis over 3 years,”
Diabetic Medicine, vol. 25, no. 1, pp. 80–85, 2008.
[68] S. A. Weinzimer, C. Ternand, C. Howard, C.-T. Chang, D. J.
Becker, and L. M. B. Laﬀel, “A randomized trial comparing
continuous subcutaneous insulin infusion of insulin aspart
versus insulin lispro in children and adolescents with type 1
diabetes,” Diabetes Care, vol. 31, no. 2, pp. 210–215, 2008.
[69] J. C. Pickup and A. J. Sutton, “Severe hypoglycaemia and
glycaemic control in Type 1 diabetes: meta-analysis of
multiple daily insulin injections compared with continuous
subcutaneous insulin infusion,” Diabetic Medicine, vol. 25,
no. 7, pp. 765–774, 2008.
[70] J. J. F. McVean, J. C. Eickhoﬀ, and M. J. MacDonald, “Factors
correlating with improved A1C in children using continuous
subcutaneousinsulininfusion,”DiabetesCare,vol.30,no.10,
pp. 2499–2500, 2007.
[71] R. Hanas and J. Ludvigsson, “Hypoglycemia and ketoacidosis
with insulin pump therapy in children and adolescents,”
Pediatric Diabetes, vol. 7, supplement 4, pp. 32–38, 2006.
[72] S. K. McMahon, F. L. Airey, D. A. Marangou, et al., “Insulin
pump therapy in children and adolescents: improvements in
key parameters of diabetes management including quality of
life,” Diabetic Medicine, vol. 22, no. 1, pp. 92–96, 2005.
[73] P. B. J´ ul´ ıusson, M. Graue, and T. Wentzel-Larsen, “The
impact of continuous subcutaneous insulin infusion on
health-related quality of life in children and adolescents with
type 1 diabetes,” Acta Paediatrica, vol. 95, no. 11, pp. 1481–
1487, 2006.
[74] L. Opipari-arrigan, E. M. Fredericks, N. Burkhart, L. Dale,
M. Hodge, and C. Foster, “Continuous subcutaneous insulin
infusionbeneﬁtsqualityoflifeinpreschool-agechildrenwith
type 1 diabetes mellitus,” Pediatric Diabetes,v o l .8 ,n o .6 ,p p .
377–383, 2007.
[75] K. D. Barnard, J. Speight, and T. C. Skinner, “Quality of life
and impact of continuous subcutaneous insulin infusion for
children and their parents,” Practical Diabetes International,
vol. 25, no. 7, pp. 278–284, 2008.
[76] O. Rackham, F. Paize, and A. M. Weindling, “Cause of death
in infants of women with pregestational diabetes mellitus
and the relationship with glycemic control,” Postgraduate
Medicine, vol. 121, no. 4, pp. 26–32, 2009.
[77] S. Hieronimus, C. Cupelli, A. Bongain, M. Durand-R` eville,
F. Berthier, and P. F` enichel, “Pregnancy in type 1 diabetes:
insulin pump versus intensiﬁed conventional therapy,” Gyne-
cologie Obstetrique Fertilite, vol. 33, no. 6, pp. 389–394, 2005.
[78] S. G. Gabbe, E. Holing, P. Temple, and Z. A. Brown,
“Beneﬁts,risks,costs,andpatientsatisfactionassociatedwith
insulin pump therapy for the pregnancy complicated by
type 1 diabetes mellitus,” American Journal of Obstetrics and
Gynecology, vol. 182, no. 6, pp. 1283–1291, 2000.
[79] Gestational Diabetes Mellitus, “American diabetes associa-
tion publication,” Diabetes Care, vol. 26, supplement 1, pp.
S103–S105, 2003.
[80] L. Chitayat, L. Jovanovic, and M. Hod, “New modalities in
the treatment of pregnancies complicated by diabetes: drugs
and devices,” Seminars in Fetal and Neonatal Medicine, vol.
14, no. 2, pp. 72–76, 2009.
[ 8 1 ]A .M u k h o p a d h y a y ,T .F a r r e l l ,R .B .F r a s e r ,a n dB .O l a ,
“Continuous subcutaneous insulin infusion vs intensive
conventional insulin therapy in pregnant diabetic women:
a systematic review and metaanalysis of randomized, con-
trolled trials,” American Journal of Obstetrics and Gynecology,
vol. 197, no. 5, pp. 447–456, 2007.14 Experimental Diabetes Research
[ 8 2 ]D .F a r r a r ,D .J .T u ﬀnell, and J. West, “Continuous sub-
cutaneous insulin infusion versus multiple daily injections
of insulin for pregnant women with diabetes,” Cochrane
Database of Systematic Reviews, vol. 18, no. 3, Article ID
CD005542, 2007.
[83] A. St John, W. A. Davis, C. P. Price, and T. M. E. Davis, “The
value of self-monitoring of blood glucose: a review of recent
evidence,” Journal of Diabetes and Its Complications, vol. 24,
no. 2, pp. 129–141, 2010.
[84] K. D. Kohnert, L. Vogt, P. Augstein, et al., “Relationships
between glucose variability and conventional measures of
glycemic control in continuously monitored patients with
type 2 diabetes,” Hormone and Metabolic Research, vol. 41,
no. 2, pp. 137–141, 2009.
[85] G. Reach and C. Choleau, “Continuous glucose monitoring:
physiological and technological challenges,” Current Diabetes
Reviews, vol. 4, no. 3, pp. 175–180, 2008.
[86] C. De Block, B. Manuel-y-Keenoy, P. Rogiers, P. Jorens, and
L. Van Gaal, “Glucose control and use of continuous glucose
monitoring in the intensive care unit: a critical review,”
Current Diabetes Reviews, vol. 4, no. 3, pp. 234–244, 2008.
[87] T. Battelino and J. Bolinder, “Clinical use of real-time
continuous glucose monitoring,” Current Diabetes Reviews,
vol. 4, no. 3, pp. 218–222, 2008.
[88] S. L. Ellis, R. G. Naik, K. Gemperline, and S. K. Garg, “Use
of continuous glucose monitoring in patients with type 1
diabetes,” Current Diabetes Reviews, vol. 4, no. 3, pp. 207–
217, 2008.
[89] R. Hovorka, “Continuous glucose monitoring and closed-
loop systems,” Diabetic Medicine, vol. 23, no. 1, pp. 1–12,
2006.
[90] H. Hanaire, “Continuous glucose monitoring and external
insulin pump: towards a subcutaneous closed loop,” Diabetes
and Metabolism, vol. 32, no. 5, pp. 534–538, 2006.
[91] I. B. Hirsch, D. Armstrong, R. M. Bergenstal, et al., “Clinical
application of emerging sensor technologies in diabetes
management: consensus guidelines for continuous glucose
monitoring (CGM),” Diabetes Technology and Therapeutics,
vol. 10, no. 4, pp. 232–246, 2008.
[92] G. Sparacino, A. Facchinetti, A. Maran, and C. Cobelli,
“Continuous glucose monitoring time series and
hypo/hyperglycemia prevention: requirements, methods,
open problems,” Current Diabetes Reviews,v o l .4 ,n o .3 ,p p .
181–192, 2008.
[93] T. Danne, K. Lange, and O. Kordonouri, “Real-time glucose
sensors in children and adolescents with type-1 diabetes,”
Hormone Research, vol. 70, no. 4, pp. 193–202, 2008.
[94] P.Grant,“Anewapproachtodiabeticcontrol:fuzzylogicand
insulin pump technology,” Medical Engineering and Physics,
vol. 29, no. 7, pp. 824–827, 2007.
[95] G. M. Steil, K. Rebrin, C. Darwin, F. Hariri, and M. F. Saad,
“Feasibility of automating insulin delivery for the treatment
of type 1 diabetes,” Diabetes, vol. 55, no. 12, pp. 3344–3350,
2006.
[96] S. A. Weinzimer, G. M. Steil, K. L. Swan, J. Dziura, N. Kurtz,
and W. V. Tamborlane, “Fully automated closed-loop insulin
delivery versus semiautomated hybrid control in pediatric
patients with type 1 diabetes using an artiﬁcial pancreas,”
Diabetes Care, vol. 31, no. 5, pp. 934–939, 2008.
[97] B. W. Bequette, “A critical assessment of algorithms and
challenges in the development of a closed-loop artiﬁcial
pancreas,” Diabetes Technology and Therapeutics, vol. 7, no.
1, pp. 28–47, 2005.
[98] A. I. Silva, A. Norton De Matos, I. G. Brons, and M. Mateus,
“An overview on the development of a bio-artiﬁcial pancreas
as a treatment of insulin-dependent diabetes mellitus,”
Medicinal Research Reviews, vol. 26, no. 2, pp. 181–222, 2006.
[99] B. Thorens, “Development and preclinical assessment of
a bioartiﬁcial pancreas,” Swiss Medical Weekly, vol. 137,
supplement 155, pp. 68S–71S, 2007.
[100] E. Renard, G. Costalat, H. Chevassus, and J. Bringer, “Artiﬁ-
cial β-cell: clinical experience toward an implantable closed-
loop insulin delivery system,” Diabetes and Metabolism, vol.
32, no. 5, pp. 497–502, 2006.
[101] N. Erdin, F. Robin, L. Heinemann, D. Brandt, and R. Hov-
orka, “Further development of artiﬁcial pancreas: blocked by
patents?” Journal of Diabetes Science and Technology, vol. 2,
no. 6, pp. 971–976, 2008.
[102] N. Kobayashi, “Bioartiﬁcial pancreas for the treatment of
diabetes,” Cell Transplantation, vol. 17, no. 1-2, pp. 11–17,
2008.